The treatment of [Ru(VI)(N)(L)(MeOH)]PF(6) (1) (L = N,N'-bis(salicylidene)-o-cyclohexyldiamine dianion) with 2 equiv of RNC (R = (a) (t)Bu, (b) Cy) in CH(2)Cl(2) affords a mixture of blue cis-beta-[Ru(III)(NCNR)(L)(CNR)] (2) and green trans-[Ru(III)(L)(CNR)(2)]PF(6) (3) products. The reduction of 3 with a stoichiometric amount of Cp(2)Co in CH(3)CN gives red trans-[Ru(II)(L)(CNR)(2)] (4). Refluxing 4 with 3 equiv of RNC in methanol in the presence of 5 equiv of NH(4)PF(6) affords a yellow complex, mer-[Ru(II)(eta(3)-HL)(CNR)(3)](PF(6)) (5), in which the ligand is in an eta(3)-coordination mode. These complexes are characterized by IR, UV-vis, ESI-MS, CV, magnetic measurements, and CHN elemental analysis. The structures of 2a, 3a, 4a, 4b, and 5a have been determined by X-ray crystallography.
No takes yet. Share an insight, caveat, or question.
Kwong et al. (2009) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: